A Study of Olverembatinib in Patients With Newly Diagnosed Ph+ ALL (POLARIS-1)
← catalyst calendarNCT06051409 · readout in 499 d
Sponsored by Ascentage Pharma Group Inc. (industry) · AAPG — their whole pipeline →. With Guangzhou Healthquest Pharma Co., Ltd.
Phase
Phase 3
Status
Recruiting
Study type
Interventional
Design
Randomized · None · Treatment
Enrollment
350estimated
Sites
90
Countries
Australia, China, Czechia +9
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2023-08-31 | actual | When the study began enrolling |
| Primary completion | 2027-12-31 | estimated | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | 2029-06-30 | estimated | The whole study's end, after follow-up |
| First posted | 2023-09-22 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2026-04-30 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Conditions
- Ph+ ALL
- Leukemia, Lymphoblastic, Acute, Philadelphia-Positive
Interventions
- Drug: Olverembatinib
- Drug: Investigator's choice of TKI
Primary outcome
what the primary-completion date above is the date OFMinimal Residual Disease Negative CR Rate
measured Cycle 1 to Cycle 3 (each cycle is 28 days)
Permalink · AAPG's whole pipeline · Catalyst calendar · Every registered study · What changed